 CRESSKILL, N.J. and JERUSALEM, May 24, 2021 GLOBE NEWSWIRE -- BrainsWay Ltd. NASDAQ TASE: BWAY BrainsWay or the Company, a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that Centene Corporation has published a positive coverage policy for Deep Transcranial Magnetic Stimulation TMS treatment of obsessive-compulsive disorder OCD using the BrainsWay Deep TMSTM system. Centene provides coverage to about 25 million members in all 50 states, including Medicaid and Medicare members, as well as to individuals and families served by the Health Insurance Marketplace, the TRICARE program, and commercial insurance. 